The company released new data from the MAXA clinical trial which compared standalone MagnetOS to the gold standard autograft in the posterior spinal fusion approach. The study found MagnetOS had a fusion rate of 78% after one year compared to 45% with the autograft.
MagnetOS Easypack puttyputty earned FDA 510(k) clearances. MagnetOs Easypack putty can be used in any interbody spaces and cages approved for use with bone void fillers.
Magnet OS putty was also cleared by the FDA for standalone use or mixed with an autograft.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
